RTOG-1112

Closed to Accrual

Return to Protocol Table

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular Carcinoma

Principal Investigator

Laura Dawson, MD

Status

Closed to Accrual

Date Opened To Accrual

April 24 2013

Date Closed to Accrual

March 10 2021

Disease Site

Gastrointestinal [GI]

Liver

Phase

III

Developmental Therapeutics

Primary Objective

To determine if SBRT improves overall survival in HCC patients treated with Sorafenib

Patient Population

Unsuitable for resection or transplant or radiofrequency ablation (RFA); Unsuitable for TACE or refractory to TACE; Barcelona Clinic Liver Cancer Stage (BCLC) Intermediate (B) or Advanced (C)

Target Accrual

292

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.